AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RGEN · NASDAQ · Medical - Instruments & Supplies

Repligen

Supplies filtration, chromatography, analytics, and protein technologies for biologics manufacturers and CDMOs.

$181.00

After-hours close+4.79 (+2.72%)

At close$176.21(−3.20%)

Something off on this page? Send us feedback.

Profile

Repligen CorporationRGENHealth Care

Sells filtration, chromatography, process-analytics, and protein technologies used by biopharmaceutical developers and CDMOs. The company operates as one reportable segment and builds its platform through internal R&D and acquisitions.

Biopharmaceutical developers and CDMOs use its Filtration, Chromatography, Process Analytics, and Proteins franchises in biologics manufacturing. Product families include OPUS chromatography columns, XCell ATF perfusion systems, KrosFlo tangential-flow filtration systems, CTech/SoloVPE analytics, and Protein A products. These tools support biologics production and span process development, purification, and production workflows.

Manufacturing is centered in the United States, with additional sites across Europe and Taiwan. The business evolved from therapeutic development into an acquisition-built bioprocessing platform and operates as one reportable segment. Technology integration, internal R&D, and acquisitions remain structural parts of the model.

Company facts

CEOOlivier Loeillot

ListedApr 29, 1986

ExchangeNASDAQ

HeadquartersWaltham, MA

CountryUnited States

Employees2,000

CIK0000730272

ISINUS7599161095

Key statistics

Market cap$9.95B

EPS (ttm)$0.7300

P/E (ttm)241.47

ROE2.0%

P/B4.71

P/S12.67

Dividend yield—

Beta1.24vs XLV 1.01

Year to date +7.2% · Average volume (30d) 1.2M

Analysts

Price target, next 12 months$152.50−13.5%Median of 24 analysts · vs the Aug 28 close

ConsensusBuy22 of 24 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $176.27

High$160.00−9.2%

Median$152.50−13.5%

Low$142.00−19.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 7, 2026	Citigroup	Upgrade		Buy
Jul 7, 2026	Benchmark	Upgrade	Hold	Buy
Jul 6, 2026	Evercore ISI	Reiterate		Outperform		$160
May 14, 2026	RBC Capital	Target			$205	$160
May 5, 2026	Jefferies	Target			$160	$142

Earnings

EPS

Estimate$0.46

ReportedDue Nov 3, 2026

Revenue

Estimate$206.8M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 28, 2026Q2 FY26	$0.45	$0.54	+20.8%	$201.6M	$204.1M	+1.3%	−2.83%
May 5, 2026Q1 FY26	$0.38	$0.48	+26.3%	$192.1M	$194.3M	+1.1%	+0.12%
Feb 24, 2026Q4 FY25	$0.44	$0.49	+11.4%	$192.9M	$197.9M	+2.6%	−1.88%
Oct 28, 2025Q3 FY25	$0.42	$0.46	+9.5%	$192.2M	$188.8M	−1.8%	−2.04%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$169.2M	$182.4M	$188.8M	$197.9M	$194.3M	$204.1M
Gross profit	$90.8M	$91.1M	$100.5M	$93.4M	$98.5M	$108.4M
Operating income	$6.6M	$13.9M	$16.8M	$18.6M	$18.0M	$11.9M
Net income	$5.8M	$14.9M	$14.9M	$13.3M	$8.3M	$5.0M
Diluted EPS	$0.10	$0.26	$0.26	$0.23	$0.15	$0.09
Gross margin	53.6%	50.0%	53.2%	47.2%	50.7%	53.1%
Operating margin	3.9%	7.6%	8.9%	9.4%	9.3%	5.8%

Fiscal years (4-quarter sums)FY21 $670.5M · FY22 $801.5M · FY23 $621.5M · FY24 $634.4M · FY25 $738.3M

Revenue by product · Q2 FY26

Product$204.1M · 100%

Royalty$43.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $810.4M · Total debt $690.9M · Total assets $2.95B · Shareholders' equity $2.11B

Dividends

No dividends on record.

Ownership

Institutions 132.36%Insiders 0.68%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 56.44M · Float 53.37M · 94.6% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	5.38M	9.54%	13F	Aug 7, 2026
FMR LLC	3.33M	5.89%	13F	Aug 13, 2026
Vanguard Capital Management	2.83M	5.00%	13G	Jul 31, 2026
United Capital Financial Advisers, LLC	2.79M	4.94%	13F	Aug 17, 2026
Vanguard Portfolio Management LLC	2.31M	4.10%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 20, 2026	Olivier Loeillot	director, officer: Chief Executive Officer	−5,426	$180.00
Jul 16, 2026	Jason K. Garland	officer: CFO	−530	$150.00
Jun 25, 2026	Jason K. Garland	officer: CFO	−733	$145.00
Apr 21, 2026	Olivier Loeillot	director, officer: Chief Executive Officer	−3,832	$140.00
Dec 17, 2025	Karen A. Dawes	director	−275	$161.00